title: [Analysis of plasma concentration of thalidomide in Japanese patients of multiple myeloma with renal dysfunction].
abstract: The serum concentration of thalidomide in multiple myeloma (MM) patients with renal insufficiency has not been investigated in Japan. We examined the serum concentration of thalidomide 12 and 16 hours after administration in 5 patients with MM (one with normal renal function and four with renal insufficiency, including one on hemodialysis (HD)) taking 100-200 mg/day. Concentrations 12 and 16 hours after administration corresponded to those before and after HD, respectively, in the patient on HD. The thalidomide concentration was not significantly increased by renal insufficiency. We could not detect any correlation between the concentration of thalidomide and its clinical effect. Since the elimination of thalidomide during HD seems to be greater than during the same period on a non-HD day, it was suggested that thalidomide could be eliminated by HD. The concentrations 12 hours after administration were similar with or without HD. From these results, even in Japanese patients, the thalidomide dosage need not be modified for renal insufficiency and HD.
authors.affiliation: Department of Hematology, Tokyo Medical and Dental University.
authors.forename: Ayako
authors.initials: A
authors.lastname: Arai
authors.forename: Ayako
authors.initials: A
authors.lastname: Hirota
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Fukuda
authors.forename: Shuji
authors.initials: S
authors.lastname: Tohda
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Mori
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Terada
authors.forename: Sei
authors.initials: S
authors.lastname: Sasaki
authors.forename: Osamu
authors.initials: O
authors.lastname: Miura
mesh_terms: D000368:Aged; D044466:Asian People; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000097:blood* / Q000493:pharmacokinetics; D007668:Kidney / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism*; D006435:Renal Dialysis; D051437:Renal Insufficiency / Q000150:complications* / Q000378:metabolism*; D013792:Thalidomide / Q000008:administration & dosage* / Q000097:blood* / Q000493:pharmacokinetics
chemical_list: D007166:Immunosuppressive Agents; D013792:Thalidomide